-
December's reviewers of the month BJU Int. (IF 3.7) Pub Date : 2024-11-19
Click on the article title to read more.
-
Focus on advances in the management of bladder and kidney cancer BJU Int. (IF 3.7) Pub Date : 2024-11-19
Click on the article title to read more.
-
Risk of bleeding after retrograde intrarenal surgery vs miniaturised percutaneous nephrolithotomy for 10–20 mm renal stones: a not so different safety profile BJU Int. (IF 3.7) Pub Date : 2024-11-19 Davide Perri, Umberto Besana, Matteo Maltagliati, Andrea Pacchetti, Tommaso Calcagnile, Antonio Luigi Pastore, Javier Romero‐Otero, Salvatore Micali, Alexander Govorov, Bashkar Somani, Evangelos Liatsikos, Thomas Knoll, Bernardo Rocco, Giorgio Bozzini
ObjectiveTo assess differences in bleeding risk between retrograde intrarenal surgery (RIRS) and minimally invasive miniaturised percutaneous nephrolithotomy (mini‐PCNL) for 10–20 mm renal stones.Patients and methodsA total of 176 patients with a renal stone between 10 and 20 mm were treated. For all patients the Stone Management According to Size‐Hardness (SMASH) score was calculated: Hounsfield units
-
Can artificial intelligence evaluate the quality of YouTube videos on erectile dysfunction? BJU Int. (IF 3.7) Pub Date : 2024-11-19 Roei Golan, Aden Swayze, Zachary M. Connelly, Justin Loloi, Kevin Campbell, Aaron C. Lentz, Kara Watts, Alexander Small, Mustufa Babar, Rutul D. Patel, Ranjith Ramasamy, Stacy Loeb
Click on the article title to read more.
-
-
What is the Standard of Care For Multifocal Low-Grade Bladder Cancer? J. Urol. (IF 5.9) Pub Date : 2024-11-18 Eugene Pietzak,Christopher B Anderson
-
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-11-16 Kwanghee Kim, Syed M. Alam, Fengshen Kuo, Ziyu Chen, Wesley Yip, Andrew B. Katims, Carissa Chu, Andrew T. Lenis, Wenhuo Hu, Gamze Gokturk Ozcan, Jie-Fu Chen, Sanaz Firouzi, Yuval Elhanati, Timothy N. Clinton, Andreas Aulitzky, Nima Almassi, Yoich Fujii, Andrew T. Tracey, Peter A. Reisz, Sadna Budhu, Jonathan A. Coleman
Background and objectiveMolecular classification of upper tract urothelial carcinoma (UTUC) can provide insight into divergent clinical outcomes and provide a biological rationale for clinical decision-making. As such, we performed multi-omic analysis of UTUC tumors to identify molecular features associated with disease recurrence and response to immune checkpoint blockade (ICB). MethodsTargeted DNA
-
Re: Comprehensive Evaluation of the Ability of Comorbidity and Health Status Indices to Improve the Prediction of Perioperative Morbidity and Long-term Survival Outcomes After Radical Cystectomy Eur. Urol. (IF 25.3) Pub Date : 2024-11-16 Alexander Lloyd, Patrick Y. Wuethrich, Christopher Soliman, Marc A. Furrer
No Abstract
-
Re: Radical Prostatectomy or Watchful Waiting in Early Prostate Cancer Eur. Urol. (IF 25.3) Pub Date : 2024-11-16 Philipp Dahm, Timothy J. Wilt
No Abstract
-
Fluorescence confocal microscopy for margin assessment in prostatectomy: IP8‐FLUORESCE study protocol BJU Int. (IF 3.7) Pub Date : 2024-11-16 Nikhil Mayor, Alexander Light, Anna Silvanto, Emma Cullen, Peng Yun Ng, Almostafa Badreldin, Bijan Khoubehi, Giles Hellawell, Francesca Fiorentino, Martin J. Connor, Taimur T. Shah, Hashim U. Ahmed, Mathias Winkler
BackgroundRadical prostatectomy (RP) represents the cornerstone of surgical treatment for prostate cancer. Assessing surgical margin status intraoperatively with current techniques remains challenging due to high costs in the context of an already stretched pathology workforce. Fluorescence confocal microscopy (FCM) is a promising technique to detect margins in prostate cancer surgery not bound by
-
Oncological microdissection testicular sperm extraction (Onco‐microTESE) outcomes for fertility preservation of patients with testicular cancer with azoospermia or severe oligoasthenoteratozoospermia BJU Int. (IF 3.7) Pub Date : 2024-11-16 Jack B. Fanshawe, Thomas Hughes, Karen Briggs, Raveen Sandher, Yacoub Khalaf, Tet Yap, Julia Kopeika, Majid Shabbir
ObjectiveTo determine the success rate of oncological microdissection testicular sperm extraction (onco‐microTESE) in patients with testicular cancer (TC) with azoospermia and severe oligoasthenoteratozoospermia (OAT; <1 million/mL sperm) and to explore any factors that may predict success.Patients and MethodsCase series of outcomes from all consecutive patients (42 testes in 38 patients) that presented
-
‘Case of the Month’ from the University of Verona, Italy—navigating the medical and surgical challenges of urinary bladder paraganglioma: insights from a clinical case BJU Int. (IF 3.7) Pub Date : 2024-11-16 Lorenzo Pierangelo Treccani, Francesco Artoni, Claudio Brancelli, Alessandro Veccia, Mirko D'Onofrio, Isabella Pichiri, Matteo Brunelli, Riccardo Giuseppe Bertolo, Alessandro Antonelli
The Case Report A 44-year-old woman came to us with a history of two paravesical masses, monitored via radiological imaging for 10 years. The patient's medical history revealed multiple episodes of pulmonary embolism after orthopaedic surgery since the age of 22 years. The patient tested negative for any form of coagulopathy. To note, the patient had developed hypertension at a young age, necessitating
-
Disruption of circadian rhythm as a potential pathogenesis of nocturia Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-14 Qi-Xiang Song, Sylvia O. Suadicani, Hiromitsu Negoro, Hai-Hong Jiang, Rita Jabr, Christopher Fry, Wei Xue, Margot S. Damaser
-
Molecular imaging of renal cell carcinomas: ready for prime time Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-14 Qianyun Wu, Hongda Shao, Wei Zhai, Gang Huang, Jianjun Liu, Jeremie Calais, Weijun Wei
-
High 11-ketotestosterone linked to shorter time to castration resistance in recurrent non-metastatic prostate cancer. J. Urol. (IF 5.9) Pub Date : 2024-11-15 Cylia Dahmani,Patrick Caron,David Simonyan,Louis Lacombe,Armen Aprikian,Fred Saad,Michel Carmel,Simone Chevalier,Eric Lévesque,Chantal Guillemette
BACKGROUND. The contribution of 11-oxygenated androgens to the progression of lethal prostate cancer (PCa) remains unresolved. We hypothesized that evaluating circulating levels of 11-oxygenated androgens, such as the androgen receptor agonist 11-ketotestosterone (11KT), could serve as a potential predictor of the onset of castration resistant prostate cancer (CRPC). METHODS. We used mass spectrometry
-
Re: Adhesive Anti-fibrotic Interfaces on Diverse Organs Eur. Urol. (IF 25.3) Pub Date : 2024-11-14 David D’Andrea, Shahrokh F. Shariat
No Abstract
-
HSD3B1, prostate cancer mortality and modifiable outcomes Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-14 Pedro F. S. Freitas, Alireza Abdshah, Rana R. McKay, Nima Sharifi
-
Metabolism, mitochondria and metastasis in kidney cancer Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-13 Louise Lloyd
A study published in Nature investigating tumour metabolism in kidney cancers provides insight into the influence of mitochondria and cellular metabolism on metastasis in this disease. In this study, a 13C-labelled nutrient, [U-13C]glucose, was administered through a peripheral intravenous line to patients with varying subtypes of renal cell carcinoma (RCC) undergoing partial or radical nephrectomy
-
Epidemiology and Risk Factors for Testicular Cancer: A Systematic Review Eur. Urol. (IF 25.3) Pub Date : 2024-11-13 Valentina Tateo, Zachary J. Thompson, Scott M. Gilbert, Victoria K. Cortessis, Siamak Daneshmand, Timothy A. Masterson, Darren R. Feldman, Phillip M. Pierorazio, Gagan Prakash, Axel Heidenreich, Peter Albers, Andrea Necchi, Philippe E. Spiess
Background and objectiveTesticular germ cell tumors (TGCTs) are globally rare, although incidence significantly varies across global geographic regions and ethnicities. Recent decades have seen an unexplained increase in incidence. This review investigates the changing epidemiology of TGCT and identifies key risk factors. MethodsA systematic review following the Preferred Reporting Items for Systematic
-
Magnetic Resonance Imaging Versus Computed Tomography Guidance for Stereotactic Body Radiotherapy in Prostate Cancer: 2-year Outcomes from the MIRAGE Randomized Clinical Trial Eur. Urol. (IF 25.3) Pub Date : 2024-11-13 Amar U. Kishan, James M. Lamb, Holly Wilhalme, Maria Casado, Natalie Chong, Lily Zello, Jesus E. Juarez, Tommy Jiang, Beth K. Neilsen, Daniel A. Low, Yingli Yang, John Neylon, Vincent Basehart, Ting Martin Ma, Luca F. Valle, Minsong Cao, Michael L. Steinberg
It has been shown that magnetic resonance imaging (MRI) guidance versus computed tomography (CT) guidance for aggressive margin-reduction (AMR) for stereotactic body radiotherapy (SBRT) in prostate cancer reduces acute toxicity, but the longer-term benefits are unknown. We performed a secondary analysis of MIRAGE, a phase 3 randomized clinical trial of MRI-guided SBRT for prostate cancer, to determine
-
Re: Duration of Androgen Deprivation Therapy with Postoperative Radiotherapy for Prostate Cancer: A Comparison of Long-course Versus Short-course Androgen Deprivation Therapy in the RADICALS-HD Randomised Trial Eur. Urol. (IF 25.3) Pub Date : 2024-11-12 Pirus Ghadjar, Daniel Zips
No Abstract
-
Cuff Conundrums: Best Practice Recommendations for Urethral Instrumentation With an Artificial Urinary Sphincter in Place. J. Urol. (IF 5.9) Pub Date : 2024-11-13 Samuel J Ivan,Joshua A Cohn,Jeffrey C Loh-Doyle,Aaron C Lentz,Jay Simhan
-
Evaluating the efficacy of physiotherapy in post‐prostatectomy continence and pelvic muscle function BJU Int. (IF 3.7) Pub Date : 2024-11-13 Wei‐Zhen Tang, Wei‐Ze Xu, Tai‐Hang Liu
Click on the article title to read more.
-
A novel approach to integrated prostate cancer diagnostics: insights from MRI, prostate biopsy, and pathology reports in a pilot study BJU Int. (IF 3.7) Pub Date : 2024-11-13 Erik Thimansson, Elin Axén, Fredrik Jäderling, Johan Styrke, Maria Nyberg, Nina Hageman, Johan Ivarsson, Gert Malmberg, Viktoria Gaspar, Magnus Törnblom
In the diagnostic pathway for early detection of prostate cancer, MRI, biopsies, and pathology are included. The shift towards ‘MRI first’ avoids unnecessary biopsies and reduces overdiagnosis [1] but demands high standards for Prostate Imaging-Reporting and Data System (PI-RADS) [2] grading and accuracy in targeted biopsies. Formulating a comprehensive assessment for optimal patient management is
-
Response to Tang et al. ‘Evaluating the efficacy of physiotherapy in post‐prostatectomy continence and pelvic muscle function’ BJU Int. (IF 3.7) Pub Date : 2024-11-13 Mifuka Ouchi, Takeya Kitta
Click on the article title to read more.
-
EndoSheath use in flexible cystoscopy: a prospective evaluation of >1000 cases BJU Int. (IF 3.7) Pub Date : 2024-11-13 Lara Ratcliffe, Brian Birch
ObjectivesTo investigate patient tolerability and safety (using urinary tract infection (UTI) as a proxy measure) following EndoSheath‐assisted flexible cystoscopy (eFC). EndoSheaths are single‐use, disposable sheaths used in FC. They reduce cystoscope turnaround times as complicated, time‐consuming and costly sterilisation is no longer necessary. This reduces patient waiting times as cystoscope idle
-
Exploring the impact of lipid stress on sperm cytoskeleton: insights and prospects Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-11 Tania E. Saez Lancellotti, María V. Avena, Abi K. Funes, María-Rosa Bernal-López, Ricardo Gómez-Huelgas, Miguel W. Fornes
-
-
-
-
-
Clinical and demographic factors linked to low-value emergency department visits in pediatric patients with spina bifida. J. Urol. (IF 5.9) Pub Date : 2024-11-12 Peter Y Cai,Erin R McNamara,Hatim Thaker,Carlos R Estrada,Hsin-Hsiao S Wang
PURPOSE Identifying factors associated with emergency visits that could be delivered at lower-cost sites may help guide population health strategies for pediatric patients with spina bifida. MATERIALS AND METHODS Emergency department encounters (2016-2023) by patients with spina bifida (< 18-years-old) in Pediatric Health Information System were identified. Absence of clinical and imaging charges was
-
Real‐world use of androgen‐deprivation therapy intensification for metastatic hormone‐sensitive prostate cancer: a systematic review BJU Int. (IF 3.7) Pub Date : 2024-11-12 Amit D. Raval, Stephanie Chen, Natasha Littleton, Niculae Constantinovici, Peter J. Goebell
ObjectiveTo conduct a systematic literature review of real‐world data (RWD) studies to summarise treatment patterns among men with metastatic hormone‐sensitive prostate cancer (mHSPC). While androgen‐deprivation therapy (ADT) is a primary treatment strategy for mHSPC, ADT intensification with androgen receptor pathway inhibitors (ARPIs) and/or chemotherapy is recommended by current guidelines and has
-
Lower pole stones 1–2 cm: navigating treatment choices BJU Int. (IF 3.7) Pub Date : 2024-11-12 Carlotta Nedbal, Bhaskar K. Somani
Lower-pole renal stones might represent a challenge in endoscopic treatment, especially for intermediate sizes (1–2 cm), that come with no strong indication or contraindication for one technique over the other [1]. The sharp infundibulopelvic angle, together with the infudibulopelvic width and length, often determine treatment choices, along with the available expertise, cost and patient choice. On
-
-
-
Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy BJU Int. (IF 3.7) Pub Date : 2024-11-12 Lars Boesen, Nis Nørgaard, Rasmus Bisbjerg, Vibeke Løgager
ObjectivesTo evaluate the additional prostate cancer detection yield and clinical implications of performing contralateral systematic biopsies in men with unilateral suspicious magnetic resonance imaging (MRI) findings undergoing MRI‐guided transperineal (TP) biopsies in an outpatient clinic.Patients and MethodsA prospective study of 655 consecutive men with unilateral MRI suspicious findings undergoing
-
-
177Lu-PSMA-617 extends progression-free survival in taxane-naive mCRPC Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-11 Maria Chiara Masone
A new phase III, randomized, controlled trial was carried out to assess the efficacy of 177Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer (mCRPC). A total of 468 patients with PSMA+ mCRPC who experienced disease progression after receiving an androgen receptor pathway inhibitor (ARPI) were randomly allocated to receive 177Lu-PSMA-617 or a different ARPI. Treatment
-
Tivozanib monotherapy outperforms combination therapy in post-ICI RCC Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-11 Maria Chiara Masone
The multicentre, randomized, phase III trial TiNivo-2 was conducted to assess the efficacy of the vascular endothelial growth factor receptor inhibitor tivozanib alone versus in combination with the immune checkpoint inhibitor (ICI) nivolumab in patients with advanced renal cell carcinoma (RCC) who had progressed during or after 1–2 previous lines of therapy including one ICI. Progression-free survival
-
The urge to advance: ICS 2024 drives innovation in continence care Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-11 Maria Chiara Masone
From 23 to 25 October 2024, Madrid hosted the 54th edition of the annual meeting of the International Continence Society (ICS), the leading multi-disciplinary event in the continence field, bringing together healthcare professionals in the fields of urology, gynaecology, physiotherapy and nursing with the common interest of treating incontinence. The future of continence was the central theme of the
-
Letter: Health Vulnerabilities of Spina Bifida Patients: Transition From Adolescents to Adults. J. Urol. (IF 5.9) Pub Date : 2024-11-11 Liangping Zhang
-
Urogeriatrics: a critical perspective for future urologists BJU Int. (IF 3.7) Pub Date : 2024-11-11 William C. Gibcus, Anne Hong, David C. Chen, Henry C.X. Yao, Anthony Ta, Marlon Perera, Joseph J. Ischia, Damien M. Bolton
Click on the article title to read more.
-
Corrigendum to “Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography on Prostate Cancer Salvage Radiotherapy Management: Results from a Prospective Multicenter Randomized Phase 3 Trial (PSMA-SRT NCT03582774)” [Eur Urol. 86(1) (2024) 52–60] Eur. Urol. (IF 25.3) Pub Date : 2024-11-09 Wesley R. Armstrong, Amar U. Kishan, Kiara M. Booker, Tristan R. Grogan, David Elashoff, Ethan C. Lam, Kevyn J. Clark, Michael L. Steinberg, Wolfgang P. Fendler, Thomas A. Hope, Nicholas G. Nickols, Johannes Czernin, Jeremie Calais
The authors regret about typological errors in the article found by Feng Qi as published in the letter to the editor of July 25, 2024 in European Urology.
-
The European Association of Urology talent incubator: bridging competencies for holistic urological care BJU Int. (IF 3.7) Pub Date : 2024-11-09 Fabian P. Stangl, Juan Luis Vásquez
Click on the article title to read more.
-
PD52-08 Adherence to Intracavernosal Injection Relative to Prescriber Choices and Patient Income: Erratum. J. Urol. (IF 5.9) Pub Date : 2024-11-08
-
Adjuvant immunotherapy for high‐risk renal cell carcinoma—now or never? BJU Int. (IF 3.7) Pub Date : 2024-11-08 Tivya Kulasegaran, Niara Oliveira, Craig Gedye, Shomik Sengupta
Click on the article title to read more.
-
The impact of progression‐directed therapy on survival in metastatic castration‐refractory prostate cancer: MEDCARE phase 3 trial BJU Int. (IF 3.7) Pub Date : 2024-11-07 Kato Rans, Karolien Goffin, Steven Joniau, Gedske Daugaard, Julie den Hartog, Lodewijk Van Wynsberge, Gert De Meerleer
BackgroundMetastatic castration‐refractory prostate cancer (mCRPC) presents a therapeutic challenge despite advancements in treatment. Once mCRPC is attained, patients face limited survival prospects. Next‐line systemic treatment (NEST) is the standard of care for progressive mCRPC, encompassing various therapeutic options with associated toxicity and costs. In patients with oligoprogressive mCRPC
-
The first step in shared decision‐making for prostate cancer screening BJU Int. (IF 3.7) Pub Date : 2024-11-07 Takeshi Takahashi
Click on the article title to read more.
-
Response to Takahashi BJU Int. (IF 3.7) Pub Date : 2024-11-07 Zen Yang Ang, Yuke‐Lin Kong, Zarith Nameyrra Md Nesran, Shaun Wen Huey Lee
Click on the article title to read more.
-
First and Second-line Treatments in Metastatic Renal Cell Carcinoma Eur. Urol. (IF 25.3) Pub Date : 2024-11-06 Regina Barragan-Carrillo, Eddy Saad, Renee-Maria Saliby, Maxine Sun, Laurence Albiges, Axel Bex, Daniel Heng, Arnaud Mejean, Robert J. Motzer, Elizabeth R. Plimack, Thomas Powles, Brian I. Rini, Tian Zhang, Toni K. Choueiri
Background and objectiveThe treatment landscape for metastatic renal cell carcinoma (mRCC) has evolved significantly in recent years, leading to improved outcomes. The aim of this review is to provide clinicians with a practical guide for selecting first- and second-line treatments on the basis of current evidence. MethodsWe critically evaluated systemic treatment strategies for mRCC. A comprehensive
-
Prostate cancer in transgender women — challenges in research and clinical care Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-11-04 Farnoosh Nik-Ahd, Jennifer T. Anger, Matthew R. Cooperberg, Stephen J. Freedland
Literature about prostate cancer in transgender women is growing, but many questions remain unanswered. Unique challenges exist in the identification of transgender women that can slow or even impair research advances in this field. Reframing our thinking about the identification of this population is imperative to help advance both research and clinical care.
-
Use and disuse of catheterizable channels as the primary method of emptying the neuropathic bladder: a single institutional cohort study. J. Urol. (IF 5.9) Pub Date : 2024-11-04 Yifan Meng Griffin,Rosalia Misseri,Joshua D Roth,Benjamin M Whittam,Pankaj Dangle,Shelly King,Kirstan K Meldrum,Martin Kaefer,Mark P Cain,Richard C Rink,Konrad M Szymanski
PURPOSE We aimed to assess long-term use of continent catheterizable urinary channels (CCCs) and explore potential risk factors for disuse. MATERIALS AND METHODS People undergoing appendicovesicostomy and Monti procedures at our institution were retrospectively reviewed (1991-2023). The main outcome was CCC disuse (not intermittently catheterizing channels as the primary method of bladder emptying)
-
Re: Maarten De Rooij, Clare Allen, Jasper J. Twilt, et al. PI-QUAL Version 2: An Update of a Standardised Scoring System for the Assessment of Image Quality of Prostate MRI. Eur Radiol. In press. https://doi.org/10.1007/s00330-024-10795-4 Eur. Urol. (IF 25.3) Pub Date : 2024-11-01 Geert Villeirs, Valeria Panebianco, Caroline M. Moore, Jelle O. Barentsz
No Abstract
-
A luminal non‐coding RNA‐based genomic classifier confirms favourable outcomes in patients with clinically organ‐confined bladder cancer treated with radical cystectomy BJU Int. (IF 3.7) Pub Date : 2024-11-01 Joep J. de Jong, James A. Proudfoot, Siamak Daneshmand, Robert S. Svatek, Vikram Naryan, Ewan A. Gibb, Elai Davicioni, Shreyas Joshi, Aaron Dahmen, Roger Li, Brant A. Inman, Paras Shah, Iftach Chaplin, Jonathan Wright, Yair Lotan
ObjectiveTo further evaluate a genomic classifier (GC) in a cohort of patients undergoing radical cystectomy (RC), as long non‐coding RNA (lncRNA)‐based genomic profiling has suggested utility in identifying a distinct tumour subgroup corresponding to a favourable prognosis in patients with bladder cancer.Patients and MethodsTranscriptome‐wide expression profiling using Decipher Bladder was performed
-
Preoperative Immersive Virtual Reality (iVR) Applied to Percutaneous Nephrolithotomy: A Prospective Randomized Clinical Study of Surgical Planning and Clinical Outcomes. J. Urol. (IF 5.9) Pub Date : 2024-10-31 Andrei D Cumpanas,Mariah C Hernandez,Amanda McCormac,Marissa Ericson,Jaylen Lee,Jaime Altamirano-Villarroel,Candices M Tran,Zachary E Tano,Sohrab N Ali,Bruce M Gao,Pengbo Jiang,Roshan M Patel,Jaime Landman,Ralph V Clayman
PURPOSE Percutaneous nephrolithotomy (PCNL) is the procedure of choice for the management of complex or large renal stones. A major challenge for the surgeon, however, is the need to assimilate the nearly 2000 static images from a CT scan into a functional mental image to enable surgical planning. Accordingly, we investigated the potential of immersive virtual reality (iVR) to enhance surgical planning
-
Radiating for Two: Quantifying Radiation Exposure to Pregnant Urologists During Percutaneous Nephrolithotomy. J. Urol. (IF 5.9) Pub Date : 2024-10-31 Sikai Song,Akin S Amasyali,Daniel Jhang,Toby Clark,Kai Wen Cheng,Kyu Park,Nicole Mack,Cliff De Guzman,Ruby Kuang,Matthew Buell,Rose Leu,Kanha Shete,Ala'a Farkouh,Elizabeth A Baldwin,Evan Seibly,Zhamshid Okhunov,D Duane Baldwin
PURPOSE Current occupational recommendations limit fetal radiation dose to 1 mSv. With increased gender diversity in urology, understanding radiation exposure during pregnancy is crucial. The purpose of this study was to determine surgeon uterine radiation dose during percutaneous nephrolithotomy (PCNL) and compare effectiveness of several radiation reduction strategies in a cadaver model. MATERIALS
-
Pelvic Lymph Node Dissection in Prostate Cancer: Update from a Randomized Clinical Trial of Limited Versus Extended Dissection Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 Karim A. Touijer, Emily A. Vertosick, Daniel D. Sjoberg, Nicole Liso, Sunny Nalavenkata, Barbara Melao, Vincent P. Laudone, Behfar Ehdaie, Brett Carver, James A. Eastham, Peter T. Scardino, Andrew J. Vickers
Background and objectiveLymph node dissection (LND) has been standard in cancer surgery for more than a century, yet evidence from randomized trials showing a benefit is scarce. We conducted a clinically integrated randomized trial comparing limited versus extended pelvic LND (PLND) during radical prostatectomy and previously reported comparable biochemical recurrence (BCR) rates. We report updated
-
Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer Nat. Rev. Urol. (IF 12.1) Pub Date : 2024-10-29 Niklas Klümper, Alexander Cox, Gottfrid Sjödahl, Florian Roghmann, Christian Bolenz, Arndt Hartmann, Viktor Grünwald, Bishoy M. Faltas, Michael Hölzel, Markus Eckstein
-
Transporting Testosterone Home: Navigating the Road to Recovery Eur. Urol. (IF 25.3) Pub Date : 2024-10-29 Vedang Murthy, Alan Dal Pra
No Abstract